Symbol="XTLB"
AssetType="Common Stock"
Name="XTL Biopharmaceuticals Ltd ADR"
Description="XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company is headquartered in Ramat Gan, Israel."
CIK="1023549"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="XTL BIOPHARMACEUTICALS LTD, C/O ALSTON & BIRD LLP, 90 PARK AVENUE, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="4786200"
EBITDA="-881000"
PERatio="None"
PEGRatio="0"
BookValue="0.6"
DividendPerShare="0"
DividendYield="0"
EPS="-0.47"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.111"
ReturnOnEquityTTM="-0.621"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.47"
QuarterlyEarningsGrowthYOY="-0.76"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="30"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.459"
EVToRevenue="-"
EVToEBITDA="-2.578"
Beta="0.914"
num_52WeekHigh="2.22"
num_52WeekLow="0.75"
num_50DayMovingAverage="1.128"
num_200DayMovingAverage="1.239"
SharesOutstanding="5449100"
DividendDate="2017-02-10"
ExDividendDate="None"
symbol="XTLB"
open="0.84"
high="0.88"
low="0.81"
price="0.81"
volume="3955.00"
latest_trading_day="2023-07-27"
previous_close="0.81"
change="-0.01"
change_percent="-0.9757%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="75"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="25"
Volume_recent_avg="11715"
Change_recent_avg="0.01"
Delta_recent_avg="0.07"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="0.8"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="25"
Aroon_momentum_negative="75"
image_negative_thumbnail_id_1="1151"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0184.jpeg"
image_negative_thumbnail_id_2="110"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0066.jpeg"
image_neutral_thumbnail_id_1="556"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0043.jpeg"
image_neutral_thumbnail_id_2="535"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0064.jpeg"
image_positive_thumbnail_id_1="670"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0038.jpeg"
image_positive_thumbnail_id_2="697"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0011.jpeg"
image_professor_thumbnail_id_1="1170"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0004.jpeg"
image_professor_thumbnail_id_2="1201"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0035.jpeg"
